| Market Cap | ₹11,561.82 CrPharmaceuticals |
|---|---|
| Net Profit Growth | 642.91%YoY Quarterly |
| Revenue TTM | ₹1,538.14 CrOperating Revenue |
| RSI | 68.26Neutral Zone |
Key highlights
- Commissioned a state-of-the-art ADC GMP manufacturing facility in Dharwad, India
- Facility supports end-to-end production including payload synthesis and linker development
- Designed to meet global regulatory standards of the US FDA and EMA
- Leverages over 25 years of expertise in high potency API manufacturing
- Positions the group as a cost-competitive CDMO partner for global biotech firms
Production Commenced — What It Means
The new facility in Dharwad marks a significant transition for Shilpa Medicare into the high-value Antibody-Drug Conjugate market. By integrating payload synthesis, linker development, and monoclonal antibody production within a single GMP-validated environment, the company addresses the complex technical demands of cytotoxic containment. This operational readiness follows stringent qualification protocols aimed at securing approvals from international bodies like the US FDA and EMA.
The infrastructure is purpose-built to facilitate commercial-scale drug substance manufacturing, bridging the gap between early-stage development and global distribution for advanced oncology treatments.
Business Overview
- Shilpa Biologicals focuses on development and contract manufacturing of complex biologics and oncology solutions
- The company operates one of India's most robust High Potency API platforms with exacting safety engineering
- Shilpa Medicare serves patients in over 80 countries with a portfolio spanning APIs and formulations
- The group maintains a strong presence in oncology, infectious diseases, and specialty segments
- Strategic focus on becoming a globally relevant CDMO partner for advanced oncology drug substances
Financial Context
Shilpa Medicare reported a robust 32.1% year-on-year revenue growth in the latest quarter, while net profit surged by 642.91% during the same period. The company maintains a healthy Piotroski Score of 7, reflecting strong financial health and operational efficiency. While the stock trailing twelve-month PE ratio of 47.52 sits above the industry average of 41.39, it remains well below its five-year average PE of 101.25.
Market momentum is evident as the share price has climbed 20.58% over the last month, currently trading near its three-year high of 598.9.
Management Perspective
The manufacturing of highly potent compounds has been a core pillar of Shilpa’s identity, and this ADC Drug Substance facility adds a new sophisticated dimension to the capabilities of the Shilpa group.
“India has the scientific talent and now, with this facility, the infrastructure as well to be a serious and trusted partner in global ADC Drug Substance manufacturing.”
| Share price | ₹591.15 |
|---|---|
| Market capitalisation | ₹11,561.82 Cr |
| Revenue (annual) | ₹1,538.87 Cr |
| Net profit (annual) | ₹243.33 Cr |
| Revenue (latest quarter) | ₹436.99 Cr+6.65% vs previous quarter |
| Net profit (latest quarter) | ₹107.79 Cr+141.78% vs previous quarter |
| P/E (TTM) | 47.52×Sector 41.42× |
| Promoter holding | 40.13%0.00% QoQ |
| FII holding | 11.07%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Shilpa Medicare Limited announcing the commissioning of a state-of-the-art ADC GMP manufacturing facility. Market figures from a third-party data provider.
